Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma

Guang Chen; Yihan Wang; Lu Wang; Wanhai Xu

doi:10.18632/oncotarget.14134

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma

Guang Chen _, Yihan Wang, Lu Wang and Wanhai Xu

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:5268-5280. https://doi.org/10.18632/oncotarget.14134

Metrics: PDF 1757 views | HTML 2482 views | ?

Abstract

Guang Chen1,*, Yihan Wang2,*, Lu Wang1, Wanhai Xu1

1Department of Urology, The 4^th Affiliated Hospital of Harbin Medical University, Harbin 150001, China

2College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China

*These authors have contributed equally to this work

Correspondence to:

Wanhai Xu, email: [email protected]

Keywords: kidney renal clear cell carcinoma, DNA methylation, prognosis, network, gene expression

Received: July 28, 2016 Accepted: November 22, 2016 Published: December 24, 2016

ABSTRACT

The outcome of kidney renal clear cell carcinoma (KIRC) differs even among individuals with similar clinical characteristics. DNA methylation is regarded as a regulator of gene expression in cancers, which may be a molecular marker of prognosis. In this study, we aimed to mine novel methylation markers of the prognosis of KIRC. We revealed a total of 2793 genes differentially methylated in their promoter regions (DMGs) and 2979 differentially expressed genes (DEGs) in KIRC tissues compared with normal tissues using The Cancer Genome Atlas datasets. Then, we detected 57 and 34 subpathways enriched among the DMGs and DEGs, respectively, using the R package iSubpathwayMiner. We retained 56 subpathways related to both aberrant methylation and expression based on a hypergeometric test for further analysis. An integrated gene regulatory network was constructed using the regulatory relationships between genes in the subpathways. Using the top 15% of the nodes from the network ranked by degree, survival analysis was performed. We validated four DNA methylation signatures (RAC2, PLCB2, VAV1, and PARVG) as being highly correlated with prognosis in KIRC. These findings suggest that DNA methylation might become a prognostic predictor in KIRC and could supplement histological prognostic prediction.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14134

Publication Alerts

Research Papers:

Identifying prognostic biomarkers based on aberrant DNA methylation in kidney renal clear cell carcinoma

Abstract